Extended-Release Ibuprofen
Mechanism of Action
Non-selective COX-1/COX-2 inhibitor. Reduces prostaglandin synthesis, decreasing inflammation, pain, and fever.
Indications
Extended-Release formulation. Pain, inflammation, fever, dysmenorrhea, arthritis. Particularly useful for musculoskeletal injuries common in lunar workers. Anti-inflammatory effect valuable for EVA-related strain and low-g adaptation pains.
Dosing
Standard (Earth)
See Extended-Release prescribing information. 200-800 mg every 6-8 hours. Maximum 3200 mg/day.
Lunar Protocol
Standard dosing applies. Monitor blood pressure (NSAIDs can elevate BP — concern in lunar hypertensive population). Limit use in residents with high radiation exposure (increased GI bleeding risk from radiation-induced mucosal damage). Prefer acetaminophen in residents on anticoagulants.
Storage
Standard
Room temperature, protect from moisture.
Lunar (Radiation + Temperature)
Store at 15-25°C. Radiation shielded storage. Tablet form preferred. 24-month supply recommended — ibuprofen is most-used NSAID in lunar environment for musculoskeletal conditions.
Supply Chain & Lunar Pharmacy Notes
WHO Essential Medicine. High consumption expected in mining and construction populations. Anti-inflammatory properties make it valuable for EVA-related musculoskeletal injury. Monitor and maintain 12-month minimum stock.
Drug Interactions
Warfarin, aspirin, lithium, diuretics, ACE inhibitors. Avoid concurrent NSAID use.
Contraindications
GI ulceration, renal impairment, cardiovascular disease, third trimester pregnancy.
Side Effects
GI upset, peptic ulcer, renal impairment, cardiovascular effects with long-term use.
Lunar Alternatives
Diclofenac, naproxen, acetaminophen, celecoxib (COX-2 selective, lower GI risk).